peptides for love handles FAQ

This scenario reflects alpha-2 receptor dominance rather than total fat mass. GLP-1 agonists are less effective here because you're not creating the caloric deficit they're designed to facilitate. Growth hormone secretagogues become the better choice at low body fat percentages. CJC-1295/ipamorelin at 200–300mcg daily combined with targeted fasted cardio increases catecholamine sensitivity in stubborn adipose depots. Expect 16+ weeks for visible changes.

Switch to tirzepatide. The dual GIP/GLP-1 mechanism produces 20–22% body weight reduction compared to semaglutide's 14.9% over similar timelines, with proportionally greater subcutaneous fat loss. Compounded tirzepatide availability expanded in 2025 following FDA shortage declarations. Another option is stacking tesofensine with a GLP-1 agonist, though regulatory approval for tesofensine remains limited to clinical trial access in most regions.

Increase the dose if you're still below 2.4mg weekly. Subcutaneous fat mobilisation scales with GLP-1 receptor saturation, and therapeutic doses typically require 16–20 weeks of exposure before flank changes become visible on DEXA or MRI. If you're already at 2.4mg and visceral fat has reduced but flanks remain, consider adding a growth hormone secretagogue like CJC-1295/ipamorelin to enhance lipolytic enzyme activity in alpha-2-dominant adipose regions.

Verify caloric deficit first. Peptides amplify fat mobilization but require energy deficit to produce net fat loss. Track intake for 7 days using a food scale and compare to estimated TDEE (total daily energy expenditure). If you're in maintenance or surplus, fat released through lipolysis is re-stored as triglycerides. Second, measure body composition beyond visual assessment. Love handles may be reducing proportionally with overall fat loss but remain visually prominent due to genetic distribution. A DEXA scan or caliper measurement at weeks 0, 4, 8, and 12 provides objective tracking.

No. Inject subcutaneously in the abdomen, thigh, or deltoid per standard protocol, but injection site does not determine fat loss location. The peptide enters systemic circulation within 20–30 minutes regardless of injection site, triggering GH release from the pituitary gland. Localized injection into adipose tissue does not increase lipolysis in that specific area. A 2018 study in The American Journal of Physiology found zero difference in fat mobilization between injection-site adipose tissue and distant sites when controlling for overall GH levels.

Combining CJC-1295/Ipamorelin with AOD-9604 or tesamorelin can increase total lipolytic signaling, but results plateau quickly due to receptor saturation. GH receptors on adipocytes have finite capacity. Elevating GH from 2× baseline to 6× baseline does not produce 3× the fat loss. Most researchers find optimal results with a single stack (CJC/Ipamorelin or tesamorelin alone) rather than multi-peptide protocols. Adding compounds increases cost and side effect risk without proportional benefit.

Genetic fat distribution determines the body fat percentage at which specific deposits become visually lean. Some individuals store preferential fat in the lower back and obliques, requiring 8–10% body fat before love handles flatten completely. Peptides cannot override this pattern. They amplify systemic fat loss but do not rewrite genetic adipocyte distribution. Continued deficit, resistance training targeting obliques and core stabilization, and patience are the only evidence-based approaches.